Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-Control Study

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals

(2016)   JOURNAL OF HYPERTENSION

Angiotensin II Receptor Blockers and Risk of Cancer in Patients With Systemic Hypertension

(2011) Chin-Chou Huang et al.   AMERICAN JOURNAL OF CARDIOLOGY

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region

(2010) E. K. K. Lam et al.   ANNALS OF ONCOLOGY

Diabetes and Cancer: A Consensus Report

(2010) E. Giovannucci et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pleiotropic Effects of Inhibitors of the RAAS in the Diabetic Population: Above and Beyond Blood Pressure Lowering

(2010) Haisam Ismail et al.   Current Diabetes Reports

Diabetes, prediabetes and cancer mortality

(2010) X. H. Zhou et al.   DIABETOLOGIA

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

(2010) S. L. Bowker et al.   DIABETOLOGIA

Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway

(2010) Yanbin Zhao et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Angiotensin-receptor blockers and cancer: urgent regulatory review needed

(2010) Steven E Nissen   LANCET ONCOLOGY

Angiotensin-receptor blockade, cancer, and concerns

(2010) Stevo Julius et al.   LANCET ONCOLOGY

Angiotensin-receptor blockade, cancer, and concerns

(2010) Mark R Goldstein et al.   LANCET ONCOLOGY

Angiotensin-receptor blockade, cancer, and concerns

(2010) Peter A Meredith et al.   LANCET ONCOLOGY

Angiotensin-receptor blockade, cancer, and concerns

(2010) Vivencio Barrios et al.   LANCET ONCOLOGY

Angiotensin-receptor blockade, cancer, and concerns

(2010) Michael Böhm et al.   LANCET ONCOLOGY

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

(2010) Ilke Sipahi et al.   LANCET ONCOLOGY

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

(2010) Sripal Bangalore et al.   LANCET ONCOLOGY

Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma

(2009) Andréia Hanada Otake et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Evaluation of a hepatitis B vaccination program in Taiwan: impact on hepatocellular carcinoma development

(2009) Isabelle Chemin   Future Oncology

Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan

(2008) Chi–Ling Chen et al.   GASTROENTEROLOGY

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: A new role in the treatment of leukaemia for these agents

(2008) Silvia De la Iglesia Iñigo et al.   LEUKEMIA RESEARCH